.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after an average consequence of 11 months, patients along with metastatic gastrointestinal lumps who acquired biomarker-matched therapies based on flowing growth DNA profiling revealed a higher professional benefit than those obtaining incomparable therapy.